FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Legal Scholars Warn Infringement by Label Will Harm Generics

[ Price : $8.95]

A new article in the New England Journal of Medicine warns that recent federal court rulings are transforming FDA-required drug la...

Turmoil Mounts Under Prasads Leadership: WSJ

[ Price : $8.95]

CBER faces mounting scrutiny after its top official, director Vinay Prasad, refused the review of Modernas flu vaccine application...

11 Observations in Eugia Pharma Inspection

[ Price : $8.95]

FDA releases the form FDA-483 with 11 observations from an inspection at Indias Eugia Pharma Specialties sterile drug manufacturin...

Inhaled Gene Therapy for Lung Cancer Gets Expedited Status

[ Price : $8.95]

FDA awards Krystal Biotech a Regenerative Medicine Advanced Therapy designation for KB707, an inhalable gene therapy being investi...

Keytruda Regimen for PD-L1Positive Ovarian Cancers Approved

[ Price : $8.95]

FDA approves Mercks Keytruda (pembrolizumab), as well as the fixed-dose combination pembrolizumab and berahyaluronidase alfa-pmph ...

FDA Tags Data Integrity, Inventory Lapses in AGC Biologics 483

[ Price : $8.95]

FDA cites AGC Biologics for deficiencies in laboratory data controls and inventory management at its Bothell, WA, drug substance m...

Biofrontera sNDA Seeks Expanded Ameluz Use

[ Price : $8.95]

FDA accepts for review a Biofrontera supplemental NDA seeking to expand the label of its photodynamic therapy drug Ameluz (aminole...

Draft Guide on Medical Gases

[ Price : $8.95]

FDA posts a draft guidance entitled Certification Process for Designated Medical Gases.

FDA Hits Tremfya TV Ad as False or Misleading

[ Price : $8.95]

The CDER Office of Prescription Drug Promotion cautions Janssen Biotech about a direct-to-consumer TV ad for Tremfya that misleadi...

CBER Head Overruled Staff on Moderna Flu Vaccine Filing

[ Price : $8.95]

CBER director Vinay Prasad overrules the Centers career reviewers in deciding to issue Moderna a refusal-to-file letter for its BL...